Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Shares Outstanding (Weighted Average): 2020-2025

Historic Shares Outstanding (Weighted Average) for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $161.5 million.

  • Xeris Biopharma Holdings' Shares Outstanding (Weighted Average) rose 8.38% to $161.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.5 million, marking a year-over-year increase of 8.38%. This contributed to the annual value of $149.1 million for FY2024, which is 7.93% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Shares Outstanding (Weighted Average) stood at $161.5 million, which was up 0.83% from $160.2 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Shares Outstanding (Weighted Average) ranged from a high of $161.5 million in Q3 2025 and a low of $59.8 million during Q1 2021.
  • Over the past 3 years, Xeris Biopharma Holdings' median Shares Outstanding (Weighted Average) value was $148.3 million (recorded in 2024), while the average stood at $146.7 million.
  • Data for Xeris Biopharma Holdings' Shares Outstanding (Weighted Average) shows a peak YoY surged of 154.63% (in 2021) over the last 5 years.
  • Xeris Biopharma Holdings' Shares Outstanding (Weighted Average) (Quarterly) stood at $124.7 million in 2021, then increased by 9.04% to $136.0 million in 2022, then rose by 1.57% to $138.1 million in 2023, then rose by 7.93% to $149.1 million in 2024, then climbed by 8.38% to $161.5 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $161.5 million for Q3 2025, versus $160.2 million for Q2 2025 and $153.9 million for Q1 2025.